Saturday 17 October 2026 Export LYEL’s income statement to Excel — free account

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024. In the quarter to June 2026, revenue fell 50.0%, EPS grew 33.6% and free cash flow grew 1.31%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

8.12 0.07 −0.85%

Follow LYEL

Alert me

Market cap: $200.7M
P/E: 0.0×
Fwd P/E: −1.6×
Dividend yield: —
F-score: 2/9
Altman Z: −5.10
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Jun '26	Mar '26	Dec '25	Sep '25	Older periods
P/E ratio Full definition →	0.00	0.00	0.00	0.00	+8 more quarters Free account
P/S ratio Full definition →	12,157.93	14,155.89	14,614.52	7,235.91
P/FCF ratio Full definition →	0.00	0.00	0.00	0.00
P/Operating CF Full definition →	(9.68)	(11.40)	(16.31)	(10.38)
P/B ratio Full definition →	1.40	1.60	2.12	0.90
Price to Tangible BV Full definition →	1.40	1.60	2.12	0.90
EV/Sales Full definition →	4,598.60	5,961.60	7,747.29	(559.80)
EV/EBITDA Full definition →	0.00	0.00	0.00	0.07
EV/Operating CF Full definition →	(0.93)	(1.38)	(1.86)	0.14
EV/FCF Full definition →	(0.71)	(1.05)	(1.45)	0.12
Quick Ratio Full definition →	5.12	6.88	5.00	10.03
Current Ratio Full definition →	5.36	7.23	5.28	10.30
Net Debt/EBITDA Full definition →	4.44	5.93	1.96	8.95
Debt/Assets Full definition →	0.00%	0.00%	0.00%	0.00%
Debt/Equity Full definition →	0.00	0.00	0.00	0.00
Asset Turnover Full definition →	0.00	0.00	0.00	0.00
Operating CF/Net income Full definition →	0.76	1.59	0.23	0.74
Capex/Depreciation Full definition →	(0.18)	(0.06)	(31.02)	0.13
Research and Development Expense of Revenue Full definition →	988,100.00%	1,830,200.00%	869,983.33%	187,813.33%
Selling, General and Administrative Expense of Revenue Full definition →	239,400.00%	477,750.00%	176,933.33%	71,246.67%
Intangible Assets out of Total Assets Full definition →	0.00	0.00	0.00	0.00
Share Based Compensation of Revenue Full definition →	113,300.00%	214,750.00%	426,150.00%	34,880.00%
Graham Net Nets Full definition →	0.41	0.43	0.32	0.84
Graham Number Full definition →	0.00	0.00	0.00	0.00
Earnings Yield Full definition →	(91.32%)	(68.79%)	(52.96%)	(141.75%)
Free Cash Flow Yield Full definition →	(53.27%)	(39.95%)	(36.44%)	(66.27%)
Revenue per Share Full definition →	0.00	0.00	0.00	0.00
Operating CF per Share Full definition →	(1.45)	(1.76)	(1.89)	(1.56)
Capex per Share Full definition →	(0.01)	0.00	(2.43)	0.01
Free Cash Flow per Share Full definition →	(1.46)	(1.76)	(4.31)	(1.55)
Cash per Share Full definition →	8.74	11.61	14.46	17.50
Shareholders Equity per Share Full definition →	10.01	12.51	14.52	18.02
Interest Debt per Share Full definition →	0.00	0.00	0.00	0.00
Book value per Share Full definition →	10.01	12.51	14.52	18.02
Free Cash Flow Full definition →	(34.17)	(38.60)	(73.73)	(28.38)
Working Capital Full definition →	173.67	230.36	211.53	296.32
Capital Expenditures Full definition →	(0.25)	(0.09)	(41.47)	0.20
Net Current Asset Value Full definition →	136.20	190.34	169.09	249.36
EV/EBIT Full definition →	0.00	0.00	0.00	0.07
Capex to Sales Full definition →	62.75	44.50	6,912.50	(13.40)
Price to Operating Income Full definition →	0.00	0.00	0.00	0.00
Other line items
Average Payables Full definition →	3.63	4.60	4.13	3.08
Average Assets Full definition →	348.30	390.21	415.46	513.59
Average Common Equity Full definition →	266.37	305.09	315.51	429.91

Show all line items

Columns are period end dates

Stockrow Weekly